This is a preview of subscription content, log in via an institution to check access.
References
Tahami Monfared AA, et al. Cost-Effectiveness of Infliximab Scheduled Maintenance Treatment for the Management of Patients With Moderate-to-Severe Ulcerative Colitis. Digestive Disease Week 2013 : abstr. Mo1325, 18 May 2013.
Odes SH, et al. The Cost-Effectiveness of Infliximab Is Different in Ulcerative Colitis and Crohn's Disease: Markov Model in a Population-Based Incident Patient Cohort. Digestive Disease Week 2013 : abstr. Mo1331, 18 May 2013.
Rights and permissions
About this article
Cite this article
Is infliximab good value for money in IBD?. PharmacoEcon Outcomes News 682, 7 (2013). https://doi.org/10.1007/s40274-013-0542-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0542-z